Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tomivosertib + PD-1/PD-L1 Inhibitor in Solid Tumors
NCT03616834Phase 2Completed
- Sponsor
- eFFECTOR Therapeutics
- Start
- Jul 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tomivosertib in Solid tumors, sponsored by eFFECTOR Therapeutics. Primary endpoints: Proportion of subjects with treatment-emergent AEs and serious AEs at 52 weeks, Overall Response Rate as determined by RECIST 1.1 at 52 weeks and 1 more. Started Jul 2018; status: completed.
02
Drugs
tomivosertib
03
Conditions
Solid tumors
Beyond the preview
Go deeper on NCT03616834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616834.